328 related articles for article (PubMed ID: 28137790)
1. Estimating
Peng G; Bojadzieva J; Ballinger ML; Li J; Blackford AL; Mai PL; Savage SA; Thomas DM; Strong LC; Wang W
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):837-844. PubMed ID: 28137790
[No Abstract] [Full Text] [Related]
2. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
[TBL] [Abstract][Full Text] [Related]
3. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
4. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.
Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):354-360. PubMed ID: 31719101
[TBL] [Abstract][Full Text] [Related]
5. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
[TBL] [Abstract][Full Text] [Related]
6. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
7. A novel TP53 germline inframe deletion identified in a Spanish series of Li-fraumeni syndrome suspected families.
Llovet P; Illana FJ; Martín-Morales L; de la Hoya M; Garre P; Ibañez-Royo MD; Pérez-Segura P; Caldés T; García-Barberán V
Fam Cancer; 2017 Oct; 16(4):567-575. PubMed ID: 28573494
[TBL] [Abstract][Full Text] [Related]
8. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
9. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing is informing phenotype: a TP53 example.
O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
[TBL] [Abstract][Full Text] [Related]
11. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of TP53 Pro72Arg and MDM2 SNP285-SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations.
Ponti F; Corsini S; Gnoli M; Pedrini E; Mordenti M; Sangiorgi L
Fam Cancer; 2016 Oct; 15(4):635-43. PubMed ID: 26956143
[TBL] [Abstract][Full Text] [Related]
13. Identification and Management of
Pal T; Brzosowicz J; Valladares A; Wiesner GL; Laronga C
South Med J; 2017 Oct; 110(10):643-648. PubMed ID: 28973705
[TBL] [Abstract][Full Text] [Related]
14. Association between Predicted Effects of
Liu Y; Axell O; van Leeuwen T; Konrat R; Kharaziha P; Larsson C; Wright APH; Bajalica-Lagercrantz S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198491
[TBL] [Abstract][Full Text] [Related]
15. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome.
Kamihara J; Rana HQ; Garber JE
Hum Mutat; 2014 Jun; 35(6):654-62. PubMed ID: 24706533
[TBL] [Abstract][Full Text] [Related]
16. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
17. Inherited
Guha T; Malkin D
Cold Spring Harb Perspect Med; 2017 Apr; 7(4):. PubMed ID: 28270529
[TBL] [Abstract][Full Text] [Related]
18. The first two confirmed sub-Saharan African families with germline TP53 mutations causing Li-Fraumeni syndrome.
Macaulay S; Goodyear QC; Kruger M; Chen W; Essop F; Krause A
Fam Cancer; 2018 Oct; 17(4):607-613. PubMed ID: 29392648
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of germline TP53 mutations and history of Li-Fraumeni syndrome in families with childhood adrenocortical tumors, choroid plexus tumors, and rhabdomyosarcoma: a population-based survey.
Magnusson S; Gisselsson D; Wiebe T; Kristoffersson U; Borg Å; Olsson H
Pediatr Blood Cancer; 2012 Nov; 59(5):846-53. PubMed ID: 22653678
[TBL] [Abstract][Full Text] [Related]
20. TP53 germline mutations in adult patients with adrenocortical carcinoma.
Herrmann LJ; Heinze B; Fassnacht M; Willenberg HS; Quinkler M; Reisch N; Zink M; Allolio B; Hahner S
J Clin Endocrinol Metab; 2012 Mar; 97(3):E476-85. PubMed ID: 22170717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
